Berenberg Bank Stick to Their Buy Rating for BioNTech SE
Investing.com
Published Nov 29, 2021 06:05AM ET
Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on BioNTech SE (NASDAQ:BNTX) on Monday, setting a price target of $400, which is approximately 14.94% above the present share price of $348.
Shu expects BioNTech SE to post earnings per share (EPS) of $13.24 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in BioNTech SE, with an average price target of $293.7.
The analysts price targets range from a high of $400 to a low of $180.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $6.09 billion and a net profit of $4.56 billion. The company's market cap is $73.91 billion.
According to TipRanks.com, Berenberg Bank analyst Zhiqiang Shu is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 1.8% and a 37.78% success rate.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.